George Mikhaeel is a Professor of Radiation Oncology at King’s College London and Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Foundation Trust since 2001. He specialises in the treatment of lymphoma with both chemotherapy and radiotherapy and has extensive experience in advanced radiotherapy techniques for haematological malignancies.

Professor Mikhaeel’s research has resulted in new ways of treating lymphoma patients with radiotherapy, harnessing the benefits of advances in radiotherapy technology and advances in imaging. An example of new treatments is combining an innovative arc technique and deep inspiration breath-hold (DIBH) with image-guided delivery of treatment to improve the accuracy of targeting radiation and reduce dose to healthy tissues.

His clinical practice is focused only on haematological malignancies which are less common and require a high level of specialisation and substantial clinical experience, having practised in this field for more 20 years. Professor Mikhaeel has lectured in more than 15 countries and has numerous publications in the field including four influential international guidelines.

He is a founding member of the International Lymphoma Radiation Oncology Group (ILROG) and a member of its steering and executive committees. Professor Mikhaeel also chairs the haematology track for the American Society of Radiation Oncology (ASTRO) annual meeting scientific committee and a reviewer for the European Society of Radiation Oncology (ESTRO). Nationally, he is the chair of the UK Lymphoma Radiotherapy Group (UK-LRG) steering committee.

• Radiotherapy
• Chemotherapy

• Haematological malignancies

Dr Peter Harper trained at University College and University College Hospital (MB BS 1970) and has been a leading consultant at Guy's and St Thomas Hospital for over 25 years. He is both an accredited physician and a medical oncologist. One of the four founder partners of the London Oncology Clinic, his vision was of a clinic dedicated solely to cancer treatment offering the highest international standards of care in a state-of-the-art supportive environment, also providing the support including all the ancillary care required by patients and their families.

Author of more than 400 papers and chapters in peer-reviewed publications, he is acknowledged globally for his work in researching new drugs and developing improved forms of cancer treatment. He has been the chair, or has been a member of many international executive committees investigating new approaches to cancer treatment, editorial boards for professional publications and is currently a member of eight pharmaceutical company advisory boards and is a member of sixteen professional bodies from around the world, including board membership of a committee of the American Society of Clinical Oncologists (ASCO).

In 2002 he was awarded the prestigious Cino del Duca Medal in 2004 in recognition of his work in developing new anti-cancer and vaccine therapies. For his role in advising the French Government in strategic cancer care (Board Member French National Cancer Institute), he was appointed a Chevalier of the Legion D'Honneur, a rare distinction for a foreign national. He remains on the board of INCA, the strategic committee for cancer treatment in France, and is currently the Chairman of the Toulouse Cancer Centre and holds the Medaille D'Or of that city.

• Chemotherapy of solid tumours
• Gynaecological cancers
• Gastrointestinal cancers
• Breast cancer
• Lung cancer
• Urological cancers

• Chemotherapy of solid tumours
• Gynaecological cancers
• Gastrointestinal cancers
• Breast cancer
• Lung cancer
• Urological cancers

Dr Rebecca Kristeleit is a Clinical Senior Lecturer and Consultant Medical Oncologist at UCL/UCLH. She specialises in the treatment of gynaecological cancers such as cervical cancer, endometrial cancer, and ovarian cancer. She also has a specialist interest in drug development as well and is leading several clinical trials of novel agents relevant to gynaecological malignancies including PARP inhibitors.

Dr Kristeleit qualified in medicine from St Andrew’s and Manchester Universities including eight months at the University of Lausanne (Switzerland) on an Erasmus scholarship. Following general medical training in London, she undertook my medical oncology training at The Royal Marsden Hospital and a CRUK-funded research fellowship at the Institute of Cancer Research. Subsequently, Dr Kristeleit spent a year as a senior research fellow on the Drug Development Unit at the Royal Marsden Hospital gaining specialist experience in the design and conduct of early phase clinical trials and translational medicine.

Dr Kristeleit's research work, as part of the UCLH gynaecological oncology team, Clinical Research Facility at UCLH and the UCL Cancer Institute, is focused on the development of early-phase clinical trials and translational research to identify and evaluate innovative treatment strategies for gynaecological malignancies as well as other solid tumours.

• Cervical cancer
• Endometrial cancer
• Ovarian cancer

• Cervical cancer
• Endometrial cancer
• Ovarian cancer

Lucy Brazil is a Consultant Oncologist who has been with Guy’s and St Thomas’ and King’s College Hospitals since 2005. In 2007, she was awarded an MD for research into breast cancer genetics at the Institute of Cancer Research and Breakthrough Breast Cancer.

Dr Brazil trained in oncology at the Royal Marsden Hospital and Guy’s and St Thomas’ Hospitals. Her specialist interests include neuro-oncology particularly high grade glioblastoma multiforme and low grade glioma including oligodendroglioma and spinal tumours and breast cancer including management of brain metastases. Dr Brazil has expertise in radiotherapy both standard conformal and stereotactic techniques and including Cyberknife, Rapid-Arc and IMRT. She also oversees chemotherapy and endocrine treatments.

Dr Brazil is a member of the NCI National Cancer Institute Brain Tumour Clinical Studies Group and the EORTC European Organisation of Research and Treatment of Cancer Brain Tumour Group. She is chief investigator for the CODEL brain tumour study using chemotherapy and radiotherapy for grade 3 gliomas, chairman of the brain-tumour palliative care sub-group and neuro-oncology research lead at Guy's and St Thomas' in addition to being systemic chemotherapy neuro-oncology lead at the hospital.

• Radiotherapy
• Chemotherapy
• Immunotherapy
• Palliative Care

• Brain Cancer
• Breast Cancer
• Neuro-oncology

Dr Vinod Mullassery is a London-based consultant clinical oncologist who specialises in urological and breast cancer management at Guy's and St Thomas' NHS Foundation Trust. He treats patients with solid tumours and uses radiotherapy, chemotherapy, hormones, and biological therapies. Dr Mullassery is the current brachytherapy lead at the hospital and also implemented the image-guided interstitial brachytherapy programme for cervical cancer.

Dr Mullassery gained his MD in 1999 before training in oncology at the University College Hospital, Great Ormond Street Hospital, and the Mount Vernon Cancer Centre, where he later undertook a post-CCT fellowship in radiotherapy techniques. In 2013, he was awarded the American Brachytherapy Society HDR Scholarship Award after spending time training at the University of California. Dr Mullassery remains involved in teaching and has tutored both undergraduate and postgraduate students. He is also involved in research and his current topics of interest are high dose rate brachytherapy and cancer imaging.

Dr Jonathan Shamash is a Consultant Oncologist and is the Lead in Acute Oncology at St Bartholomew’s Hospital and has a further NHS base at Queen’s Hospital, Romford. Dr Shamash also sees patients privately, including at Leaders in Oncology Care. He graduated from the University of Edinburgh in 1987 and then undertook post graduate training in London, gaining an MD in in-vitro modelling of lymphoma.

Dr Shamash sub-specialises in genito-urinary cancers and thoracic malignancies. He has a special interest in managing complex oncology problems and delivering intensive treatments, including high dose Interleukin-2 and high does chemotherapy in testicular cancer. . Dr Shamash also chairs the supra-regional germ cell tumour multidisciplinary meeting and is a member of the NCRI testis clinical studies group. He leads various clinical studies in the management of testicular and prostate cancer and has published widely.

Dr Anita Mitra is a Consultant in Clinical Oncology based at University College London Hospitals NHS Foundation Trust and she also sees patients privately. She specialises in the treatment of urological cancers including prostate, bladder, testicular and advanced penile cancer.

Diseases, Medical Tests and Treatments

• Radiotherapy

• Prostate Cancer

Prof Siow Ming Lee is Professor of Medical Oncology and Consultant Medical Oncologist at University College London Hospital (UCLH). He is an internationally recognised authority on lung cancer treatment and research.

He has led several National Cancer Research Institute (NCRI) lung cancer trials over the past three decades in UK, which have changed clinical practice and improved treatment outcomes for lung cancer patients.

His research team established the use of gemcitabine/carboplatin chemotherapy to treat lung cancer and this treatment remains the standard chemotherapy combination to treat squamous lung cancer. His innovative trials with thalidomide as a cancer weapon and the smart drug erlotinib to treat poor performance lung cancer patients received worldwide publicity including being featured on BBC Ten O’Clock News at launch. His ET trial was the first prospective biomarker chemotherapy trial with ERCC1 to select lung cancer patients for doublet chemotherapy and demonstrated that platinum combination is superior to non-platinum chemotherapy. His latest trials examine the role of atezolizumab immunotherapy to treat poor performance non-small cell lung cancer patients (IPSOS) and hydroxychloroquine to treat small cell lung cancer (Study 15). His team was also part of the international FLAURA and KEYNOTE-189 Investigators that established osimertinib and chemotherapy-pembrolizumab combination as standard first-line therapy to treat EGFR mutant and wild-type lung cancer respectively. His trials have been recognised at major international conferences with many invited Presidential, Plenary and Oral Presentations at World Lung Cancer Conference, ASCO and ESMO and resulted in several 1st or senior author publications in high impact journals. His practice-changing trials and 4* high impact research publications were used for the REF 2014 exercise which ranked UCL top for research in UK.

Professor Lee is the Clinical Lead for the UCLH Thoracic Medical Oncology Unit and chairs the London Lung Cancer Group, which has an international research reputation. He previously was chairperson for the NCRI Lung Cancer Advanced Disease Subgroup, NCRI Brain New-agents Clinical Subgroup and committee member of CTACC, NCRI Lung, NCRI Brain and NCRI Lymphoma Groups.

• Targeted therapies and immunotherapy for lung cancer 

• Non-small cell lung cancer
• Small lung cell cancer 
• Malignant mesothelioma
• Thymic carcinoma 
• HIV-related cancers

Dr Sarker is a Senior Lecturer and Honorary Consultant in Medical Oncology at Guy’s and St Thomas’ NHS Foundation Trust, and King’s College Hospital NHS Foundation Trust. He specialises in the treatment of hepato-pancreatic-biliary malignancies: Liver Cancer, Bile Duct Cancer, Pancreatic Cancer, Neuro-endocrine Cancer, Adrenal Glands Cancer and Gall Bladder Cancer.

His main research focus is in the development of novel therapies for cancer, and together with Dr James Spicer, runs the Early Phase Clinical Trials Unit based at Guy’s Hospital. He is also actively involved in the management of hepato-pancreatic-biliary malignancies at King's College Hospital Liver Unit, and has a specific interest in the development of new therapies and molecular imaging for these tumours. Dr Sarker graduated in medicine from the University of Liverpool in 1997, and subsequently trained in internal medicine and medical oncology. In 2003 he was appointed to a Cancer Research UK Clinical Research Fellowship in the Drug Development Unit of The Royal Marsden Hospital and Institute of Cancer Research, leading to the award of a PhD. He completed his medical oncology training at The Royal Marsden in 2010.

• Chemotherapy
• Molecular Imaging

• Gastro-intestinal cancers
• Neuro-endocrine cancers
• Liver cancer
• Bilary cancer

Dr Anne Armstrong is a well-respected Consultant Oncologist with HCA Healthcare and Guy's and St. Thomas' NHS Foundation Trust in London where she is the Head of Medical Oncology, along with being the lead for Systemic Treatment of Breast Cancer in South East London.

She graduated with a degree in Psychology and returned to university to study Medicine at the renowned Imperial College London. She completed her medical oncology training at numerous centres of excellence, including the Royal Marsden Hospital and Hammersmith Hospital. Following this she completed pioneering research into the molecular genetics of breast and pancreatic cancer and was awarded a PhD. In 2005 she was appointed her first Consultant post. She remains heavily involved in research, being appointed as chief investigator and of numerous breast cancer trials.

• Chemotherapy
• Hormonal Therapy
• Endocrine Therapy

• Breast Cancer